Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chin retrusion~* In good general health~Exclusion Criteria:~* Permanent facial implants on the face and/or neck~* Received fat injections below the nose~* Tattoos, piercings, beard, mustache, and/or scars on the face below the nose~* Received semi-permanent dermal fillers in the chin or jaw line in the last 3 years~* Undergone dermal filler injections or had any surgery in the chin or jaw area in the last 2 years~* Received dermal filler injections in the lips or in the mouth area in the last 12 months~* Undergone mesotherapy or cosmetic treatment (e.g., laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, liposuction, lipolysis, or other ablative procedures) anywhere in the face or neck in the last 6 months~* Received botulinum toxin treatment below the nose in the last 6 months

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JUVÉDERM VOLUMA® XC (Type: EXPERIMENTAL): JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.
- No Treatment then JUVÉDERM VOLUMA® XC (Type: OTHER): No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.

Based on this trial design, predict the completion outcome and termination type (if applicable).